Alnylam Pharmaceuticals (ALNY) cash: $1.7B
Alnylam Pharmaceuticals held $1.7B in cash and cash equivalents on Dec 31, 2025, up 71.5% from $966M a year earlier.
From Alnylam Pharmaceuticals's filings with the SEC · Read the filing · ALNY stock page
Alnylam Pharmaceuticals cash by year
#340 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $1.7B | +71% |
| Dec 31, 2024 | $966M | +19% |
| Dec 31, 2023 | $813M | -6% |
| Dec 31, 2022 | $866M | +6% |
| Dec 31, 2021 | $820M | – |
Cash of similar companies
Companies in the same industry as Alnylam Pharmaceuticals, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Alnylam Pharmaceuticals | $1.7B | Dec 31, 2025 |
| United Therapeutics | $1.6B | Dec 31, 2025 |
| Roivant Sciences | $1.5B | Dec 31, 2025 |
| Jazz Pharmaceuticals | $1.4B | Dec 31, 2025 |
| Viatris | $1.3B | Dec 31, 2025 |
| Biomarin Pharmaceutical | $1.3B | Dec 31, 2025 |
| Bausch Health Companies | $1.3B | Dec 31, 2025 |
Questions and answers
What is Alnylam Pharmaceuticals's cash?
Alnylam Pharmaceuticals held $1.7B in cash and cash equivalents on Dec 31, 2025, up 71.5% from $966M a year earlier.
Numbers as reported in Alnylam Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology